Lincoln Alternative Strategies LLC's 13G Filing for Calidi Biotherapeutics, Inc.

Lincoln Alternative Strategies LLC has filed a Schedule 13G with the SEC, disclosing its beneficial ownership of 730,000 shares of Calidi Biotherapeutics, Inc.'s common stock, representing 14.46% of the total outstanding shares. The filing indicates that Lincoln Alternative Strategies LLC has sole voting and dispositive power over these shares. The shares were not acquired for the purpose of influencing the control of the issuer. The filing was made under Rule 13d-1(c) and includes certifications that the shares were not acquired to influence control or as part of a transaction with that purpose. The filing is signed by Stephen Temes, Managing Member of Lincoln Alternative Strategies LLC.